Taiwan Regulators Clear Phase I Trial for Eden BioCell's Autologous CAR T-Cell Leukemia Treatment

NEW YORK – The Taiwan Food and Drug Administration has cleared an investigational new drug application allowing Eden BioCell to begin a Phase I clinical trial to evaluate its autologous CD19-specific CAR T-cell therapy in relapsed CD19-positive leukemias and lymphomas, Ziopharm Oncology said on Monday.